Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.35 |
| ▸ | FPR3 | P25089 | 2/20 | 0.35 |
| ▸ | TSPO | P30536 | 2/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PRNP | P04156 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277088 | 0.85 | CRHR1 (0.35) | CRHR1FPR3TSPOTMEM97LMNA | |
| SCHEMBL1638418 | 0.85 | CRHR1 (0.43) | CRHR1FPR3TSPOTMEM97LMNA | |
| SCHEMBL1762920 | 0.83 | CRHR1 (0.35) | CRHR1FPR3TSPOTMEM97HPGD | |
| SCHEMBL1762665 | 0.82 | CRHR1 (0.35) | CRHR1FPR3TSPOTMEM97RXFP1 | |
| SCHEMBL1636385 | 0.73 | CRHR1 (0.43) | CRHR1FPR3TSPOTMEM97RXFP1 | |
| SCHEMBL12593286 | 0.73 | CRHR1 (0.36) | CRHR1LMNAL3MBTL1HPGDHTT | |
| SCHEMBL1636320 | 0.72 | CRHR1 (0.36) | CRHR1FPR3TSPOTMEM97HPGD | |
| SCHEMBL12593381 | 0.72 | CRHR1 (0.33) | CRHR1KDM4EALDH1A1 | |
| SCHEMBL5311531 | 0.72 | ESR2 (0.32) | — | |
| SCHEMBL1636991 | 0.71 | CRHR1 (0.35) | CRHR1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293670-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with Tetrahydropyridine as Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293670-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with Tetrahydropyridine as Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293670-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with Tetrahydropyridine as Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1781652-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH TETRAHYDROPYRIDINE AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006001501-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH TETRAHYDROPYRIDINE AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293670-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with Tetrahydropyridine as Crf Antagonists | HRH4, HRH2, HRH1 | CRHR1 4/4885FPR3 163/4885TSPO 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.